SureTrader Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Threshold Pharmaceuticals Inc. (THLD)

THLD RSS Feed
Add THLD Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 4/30/2016 11:37:06 AM - Followers: 142 - Board type: Free - Posts Today: 0

Threshold Pharmaceuticals, Inc (THLD) 

 

 

http://www.thresholdpharm.com/

 

 



Company Address:
1300 Seaport Boulevard, Suite 500

Redwood City, CA 94063

605.474.8200

 

CIK:  0001183765


Threshold
is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional drugs.

 

Management:  http://www.thresholdpharm.com/sec/management

 



http://www.thresholdpharm.com/sec/tumor_hypoxia

 

 


Clinical Pipeline:
 http://www.thresholdpharm.com/sec/clinical_pipeline

Product Pipeline: 
TH-302 is a hypoxia-activated prodrug (HAP) for the potential treatment of solid tumors. TH-302, which was discovered at Threshold, is a novel drug candidate that is activated under the metabolic conditions typical of cancer cells. We filed an IND (Investigational New Drug) with the FDA in April 2007 and started a Phase 1 clinical trial in July 2007. We initiated a second clinical trial of TH-302 in August 2008. This Phase 1/2 clinical trial is also focused on treating solid tumors.

Glufosfamide has been investigated for the potential treatment of pancreatic cancer, small cell lung cancer, platinum-resistant ovarian cancer and advanced soft tissue sarcoma. The soft tissue sarcoma trial provided evidence of clinical activity. Additionally, in a phase 2 clinical trial of glufosfamide in combination with gemcitabine for the treatment of advanced pancreatic cancer, the data indicated that glufosfamide plus gemcitabine may benefit patients with chemotherapy naive pancreatic cancer. The Company will be seeking a partner to continue development of glufosfamide in cancer.

2-Deoxyglucose, or 2DG, for the treatment of solid tumors, has been evaluated in a Phase 1 clinical trial alone and in combination with Taxotere.

 

Recent News: 

http://finance.yahoo.com/q/h?s=THLD+Headlines

 

 

Filings:  http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001183765&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

 

 

 

Transfer Agent:
Mellon Investor Services LLC
85 Challenger Road
Ridgefield Park, NJ 07660
800.356.2017

BNYMellon Shareowner Services

 

Share Structure:

Outstanding Shares

33,702,242 as of Oct 31, 2010

 

Authorized Shares

150,000,000 as of Sep 30, 2010

 

Preferred Shares Authorized

2,000,000 as of Sep 30, 2010

 

No Preferreds Issued or Outstanding as of Sep 30, 2010

 

 

 

 

Investor Relations:
Denise T. Powell
Threshold Pharmaceuticals
650.474.8206

 

 

 

 

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:
http://investorshub.advfn.com/boards/complex_terms.asp

 

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
THLD
Current Price
Volume:
Bid Ask Day's Range
Wiki
SureTrader
THLD News: Additional Proxy Soliciting Materials (definitive) (defa14a) 04/29/2016 05:08:32 PM
THLD News: Proxy Statement (definitive) (def 14a) 04/29/2016 04:43:54 PM
THLD News: Statement of Changes in Beneficial Ownership (4) 04/29/2016 04:06:32 PM
THLD News: Current Report Filing (8-k) 04/22/2016 05:26:28 PM
THLD News: Threshold Pharmaceuticals Appoints Stew Kroll as Chief Operating Officer 03/21/2016 08:00:00 AM
PostSubject
#3152   so... in your opinion, which direction is more vip1999 04/30/16 11:37:06 AM
#3151   Bollinger bands are getting tighter, which means one trop 04/29/16 10:02:53 PM
#3150   The well funded traders are manipulating this stock....that PithicusKong 04/29/16 05:04:21 PM
#3149   Can't wait to see more "red" trading next week. R2DT 04/29/16 04:02:26 PM
#3148   Wow, is it going to close red again? R2DT 04/29/16 04:00:52 PM
#3147   What a horrible lack luster POS this stock R2DT 04/29/16 03:18:46 PM
#3146   it sounds like the company shot itself in hardtogetnewalias 04/28/16 05:22:46 AM
#3145   Being optimistic is not a bad thing. ;) hardtogetnewalias 04/27/16 05:28:18 PM
#3144   If your EPS estimate comes close....how do you PithicusKong 04/27/16 02:59:06 PM
#3143   Honestly I try to do my research rather ChrisEchavarria 04/27/16 11:49:05 AM
#3142   Yes, after further research I found information indicating ChrisEchavarria 04/27/16 11:24:34 AM
#3141   Morning Chris. what are your Q1 expectations? hardtogetnewalias 04/27/16 07:07:34 AM
#3140   isn't the next Q due BMO April 28th? Icanslim 04/26/16 09:13:35 PM
#3139   Ok. That explaines it. Thanks for your reply Chris hardtogetnewalias 04/26/16 03:41:15 PM
#3138   Clinical pretrial for the evofosfamide (TH-302) were thought ChrisEchavarria 04/26/16 02:57:41 PM
#3137   Hi. Im new to thld. Why did this hardtogetnewalias 04/26/16 02:16:31 PM
#3136   Lot of guessing and finger crossing going on. R2DT 04/26/16 12:41:29 PM
#3135   Less than 1/2 an hour for this to PithicusKong 04/26/16 09:56:16 AM
#3134   Also another negative near term is earnings release trop 04/21/16 08:27:48 PM
#3133   The only concern I have presently is that PithicusKong 04/21/16 12:24:02 PM
#3132   Patience, my friend, patience. trop 04/20/16 08:46:55 PM
#3131   Think this will be a winner but the R2DT 04/20/16 11:47:49 AM
#3130   SOS R2DT 04/19/16 06:33:34 PM
#3129   Doesn't anyone find the trading ( tiny volume PithicusKong 04/19/16 10:10:28 AM
#3128   Your opinion is very correct....it is a very PithicusKong 04/18/16 09:46:54 PM
#3127   Article was written by George Mack of The trop 04/18/16 09:44:43 PM
#3126   When was this available to the public...the only PithicusKong 04/18/16 09:25:41 PM
#3125   "The Life Sciences Report: Do you have another trop 04/18/16 08:00:25 PM
#3124   Thanks for the response....have a great weekend. PithicusKong 04/16/16 10:39:17 AM
#3123   I have no clue. I buy based on trop 04/16/16 09:47:22 AM
#3122   Was there any pump ( paid promo ) PithicusKong 04/16/16 08:37:54 AM
#3121   Anticipation of upcoming catalysts should help close the trop 04/16/16 12:41:02 AM
#3120   No Gap fill at .35 due to double trop 04/16/16 12:38:01 AM
#3119   Well...looks like it's had a couple of PithicusKong 04/15/16 01:43:09 PM
#3118   I hope you are right, nice volume with vip1999 04/15/16 11:38:48 AM
#3117   I think it was .35c......filling a gap was PithicusKong 04/15/16 11:23:59 AM
#3116   I'm hoping at least 4.16 before I get ChrisEchavarria 04/15/16 11:16:31 AM
#3115   THLD .53 +22% all bottom consolation/ accumulation, above PAC 04/15/16 11:14:32 AM
#3114   THLD .53 +22% all bottom consolation/ accumulation, above PAC 04/15/16 11:14:32 AM
#3113   I hope it makes it back to $3 vip1999 04/15/16 10:27:41 AM
#3112   ?????...meaning? PithicusKong 04/15/16 09:54:31 AM
#3111   THLD .43 worth watch bio run PAC 04/15/16 12:36:58 AM
#3110   Not to be critical here ( actually yes PithicusKong 04/14/16 10:08:20 AM
#3109   Agreed. jcJet12 04/13/16 07:48:17 PM
#3108   I DONT KNOW WHY EVERYONE THINKS IT SHOULD sell sell 04/13/16 06:41:33 PM
#3107   Too much churning within a very tight range PithicusKong 04/13/16 12:32:34 PM
#3106   There appears to be a trading Vendetta against PithicusKong 04/12/16 10:32:26 AM
#3105   I'm about ready to take my money elsewhere. R2DT 04/11/16 07:22:02 PM
#3104   It's all about the people. R2DT 04/11/16 07:18:47 PM
#3103   POS R2DT 04/11/16 07:17:36 PM
PostSubject